Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00415064 | Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma | completed | Phase 1 | 32 | AEterna ZentarisINDUSTRY | 1 | Jul 6, 2012 | clinicaltrials |
| NCT00925821 | Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 146 | Wuerzburg University HospitalOTHER | 1 | Jun 28, 2012 | clinicaltrials |
| NCT00660166 | Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions | completed | Phase 1 | 13 | Tufts Medical CenterOTHER | 1 | Jun 27, 2012 | clinicaltrials |
| NCT00312845 | Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | completed | Phase 3 | 676 | Millennium Pharmaceuticals, Inc.INDUSTRY | 32 | Jun 25, 2012 | clinicaltrials |
| NCT01524445 | Retrospective Survey of Re-treatment With Bortezomib | completed | — | 35 | Janssen Pharmaceutica N.V., BelgiumINDUSTRY | 1 | Jun 12, 2012 | clinicaltrials |
| NCT00575068 | Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 42 | BiogenINDUSTRY | 1 | Jun 8, 2012 | clinicaltrials |
| NCT00186589 | 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL | completed | Phase 1 | 30 | Stanford UniversityOTHER | 1 | Jun 6, 2012 | clinicaltrials |
| NCT00998270 | Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma | unknown | Phase 2 / Phase 3 | 185 | Tehran University of Medical SciencesOTHER | 1 | Jun 4, 2012 | clinicaltrials |
| NCT01010243 | Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial(MM03) | unknown | Phase 1 / Phase 2 | 54 | University of RegensburgOTHER | 1 | May 30, 2012 | clinicaltrials |
| NCT00427557 | Cellular Therapy With Cord Blood Cells | completed | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2012 | clinicaltrials |
| NCT00383097 | Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma(ALDI) | terminated | Phase 1 | 6 | Baylor College of MedicineOTHER | 1 | May 24, 2012 | clinicaltrials |
| NCT00420849 | A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 587 | Celgene CorporationINDUSTRY | 5 | May 21, 2012 | clinicaltrials |
| NCT01314625 | A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients | unknown | — | 10 | University of ArkansasOTHER | 1 | May 16, 2012 | clinicaltrials |
| NCT00186355 | Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma | completed | N/A | 97 | Stanford UniversityOTHER | 1 | May 14, 2012 | clinicaltrials |
| NCT01492881 | Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 11, 2012 | clinicaltrials |
| NCT00234169 | A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone | completed | Phase 1 / Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 10, 2012 | clinicaltrials |
| NCT00162955 | Prevention of CHOP-induced Chronic Cardiotoxicity | completed | Phase 4 | 150 | Osaka City UniversityOTHER | 1 | May 8, 2012 | clinicaltrials |
| NCT00725231 | Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP(A-CHOP-14) | unknown | Phase 3 | 274 | University of GöttingenOTHER | 1 | May 7, 2012 | clinicaltrials |
| NCT00514475 | Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma | completed | Phase 2 | 160 | Oslo University HospitalOTHER | 1 | May 4, 2012 | clinicaltrials |
| NCT00128921 | Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 18 | University of ArkansasOTHER | 1 | Apr 26, 2012 | clinicaltrials |
| NCT00704691 | Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas | terminated | Early Phase 1 | 1 | University of Alabama at BirminghamOTHER | 1 | Apr 20, 2012 | clinicaltrials |
| NCT01263899 | A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies | completed | Phase 2 | 28 | S*BIOINDUSTRY | 2 | Apr 20, 2012 | clinicaltrials |
| NCT00089453 | Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant | completed | Phase 1 | 10 | University of ArkansasOTHER | 1 | Apr 19, 2012 | clinicaltrials |
| NCT00171925 | Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I | terminated | Phase 3 | 143 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 11, 2012 | clinicaltrials |
| NCT00366106 | Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma | terminated | Phase 2 | 32 | Accelerated Community Oncology Research NetworkOTHER | 1 | Apr 6, 2012 | clinicaltrials |
| NCT01006070 | Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine | completed | — | 50 | University of California, San FranciscoOTHER | 1 | Mar 21, 2012 | clinicaltrials |
| NCT00333190 | CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation | completed | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 16, 2012 | clinicaltrials |
| NCT01555359 | Telomerase Activity as a Marker For Mobilization Quality | unknown | — | 50 | Rabin Medical CenterOTHER | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00799461 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | completed | Phase 3 | 1,337 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | Mar 7, 2012 | clinicaltrials |
| NCT00432562 | A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer. | completed | Phase 1 | 31 | Mast Therapeutics, Inc.INDUSTRY | 1 | Feb 23, 2012 | clinicaltrials |
| NCT01452334 | Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 0 | Feb 23, 2012 | clinicaltrials |
| NCT00475332 | Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar | terminated | Phase 2 | 2 | University of FloridaOTHER | 1 | Feb 15, 2012 | clinicaltrials |
| NCT00764829 | Blood Samples to Evaluate Biomarkers of Donor Chimerism | completed | — | 80 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2012 | clinicaltrials |
| NCT01532856 | Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years | unknown | Phase 3 | 64 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 1 | Feb 15, 2012 | clinicaltrials |
| NCT00116961 | Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma | completed | Phase 2 | 40 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 7, 2012 | clinicaltrials |
| NCT00135187 | Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma | completed | N/A | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 7, 2012 | clinicaltrials |
| NCT01527422 | Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL(CHOP-R) | completed | Phase 1 / Phase 2 | 60 | Fernando CabanillasOTHER | 1 | Feb 7, 2012 | clinicaltrials |
| NCT00091676 | Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma(BiovaxID) | unknown | Phase 3 | 629 | Biovest InternationalINDUSTRY | 0 | Feb 3, 2012 | clinicaltrials |
| NCT00029224 | Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions | completed | Phase 4 | 500 | NovartisINDUSTRY | 1 | Feb 1, 2012 | clinicaltrials |
| NCT00143871 | Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma | completed | Phase 2 | 35 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 1, 2012 | clinicaltrials |
| NCT00608907 | An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) | completed | Phase 1 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 30, 2012 | clinicaltrials |
| NCT00144677 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00144703 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation | completed | Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00531453 | A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 98 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 26, 2012 | clinicaltrials |
| NCT01517581 | Brown Fat Activity and White Fat Accumulation | completed | — | 32 | Children's Hospital Los AngelesOTHER | 1 | Jan 25, 2012 | clinicaltrials |
| NCT01513603 | Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia | unknown | Phase 2 | 50 | New York Medical CollegeOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT00427765 | Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma | completed | Phase 2 | 168 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 19, 2012 | clinicaltrials |
| NCT00048230 | PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 620 | Millennium Pharmaceuticals, Inc.INDUSTRY | 13 | Jan 13, 2012 | clinicaltrials |
| NCT00063726 | A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 | completed | Phase 3 | 600 | Millennium Pharmaceuticals, Inc.INDUSTRY | 13 | Jan 13, 2012 | clinicaltrials |
| NCT00636792 | A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma(VERTICAL) | completed | Phase 2 | 73 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 13, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Jul 6, 2012source: clinicaltrials